Author/Authors :
Cao, Xiaoqin Department of Cancer Epidemiology - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, China , Liu, Shuzheng Department of Cancer Epidemiology - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, China , Jia, Manman Gynecologic Oncology Department - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou,Henan, China , Chen, Hongmin pathology Department - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou,Henan, China , Zhao, Dongmei Molecular Pathology Department - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou,Henan, China , Dong, Bing Central Laboratory - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, Henan, China , Guo, Zhen pathology Department - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou,Henan, China , Ren, Lingyan pathology Department - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou,Henan, China , Zhang, Shaokai Department of Cancer Epidemiology - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, China 2 Liu, Shuzheng Department of Cancer Epidemiology - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, China , Sun, Xibin Department of Cancer Epidemiology - Affiliated Cancer Hospital of Zhengzhou University - Henan Cancer Hospital, Zhengzhou, China
Abstract :
Context. Human papillomavirus (HPV) testing is widely used in cervical cancer screening in women; however, its efficiency intriaging women with atypical squamous cells of undetermined significance (ASC-US) needs to be validated.Objective.Toevaluate the performance of HPV16/18 in the triage of women with ASC-US.Methods. Women presenting for routine cervicalcancer screening had cervical specimens collected, with which both liquid-based cytology (LBC) and hrHPVs were examined;those with ASC-US cytology underwent colposcopy. HPV16/18 and 12 other types were tested with domestic hybridizationcapture and chemiluminescence signal amplification (DH3). Performance characteristics of HPV test (sensitivity, specificity,positive predictive value (PPV), negative predictive value (NPV) for identification of cervical intraepithelium neoplasma (CIN)grade 2 or worse (CIN2+), and CIN grade 3 or worse (CIN3+)) were determined using standard statistical tests.Results. 317women with ASC-US were eligible for the study. HrHPV prevalence was 15.77% (50/317); HPV16/18 prevalence was 3.61%(20/317). Sensitivity and specificity of HPV16/18 for detection of CIN 2+ were 64.71% and 97% and 64.29% and 96.37% fordetection of CIN 3+, respectively. The positive predictive values (PPVs) and negative predictive values (NPVs) of HPV16/18were 55.00% and 97.98% for CIN2+ and 45.00% and 98.32% for CIN3+, respectively.Conclusion. HPV16/18 can be consideredas an effective method to triage women with ASC-US as its good clinical performance.Trial Registration. This trial is registeredwith Henan Cancer Hospital Medical Ethics Committee on July 5, 2016 (http://www.anti-cancer.com.cn), with registryno.: 2016037.
